Therapy Directory

Lenalidomide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Lenalidomide as a study intervention. Browse Lenalidomide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

703

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Myeloma
Interventions: Thalidomide, Lenalidomide, Questionnaires; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Central Nervous System Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Central Nervous System Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions: Nivolumab, Rituximab, Lenalidomide; Biological · Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Urinary Bladder Neoplasms
Interventions: Lenalidomide; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Bethesda, Maryland • New York, New York • Salt Lake City, Utah

Conditions: Prostate Cancer
Interventions: Revlimid; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Multiple Myeloma
Interventions: Ixazomib, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 20
States / cities: Berkeley, California • Duarte, California • Stanford, California + 15 more

Conditions: Multiple Myeloma
Interventions: Stem cell transplant x 1 or x 2, lenalidomide and dexamethasone; Procedure · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more

Conditions: Polycythemia Vera
Interventions: ruxolitinib tablets, Best Available Therapy (BAT); Drug · Other
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 28
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Pomona, California + 25 more

Conditions: Myeloma
Interventions: Panobinostat, Bortezomib, Lenalidomide, Dexamethasone, Symptom Questionnaire; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Cancers
Interventions: Ipilimumab, Lenalidomide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory
Interventions: Ibrutinib, DA-EPOCH-R, Lenalidomide; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • Orange, California + 7 more

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Lenalidomide, Dexamethasone, Bortezomib; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Allogeneic Myeloma Vaccine, Prevnar-13; Drug · Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

About this Lenalidomide clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Lenalidomide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lenalidomide.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Lenalidomide clinical trials

Filter and sort this therapy

Live official records

Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)

Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma

Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma

Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer

Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Ipilimumab and Lenalidomide in Advanced Cancer

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

About this Lenalidomide clinical trials directory page